In the same weeks that international rating agencies are adjusting their outlook on Mexico downwards, eight pharmaceutical companies, both national and international, sat down with President Claudia Sheinbaum to announce investment commitments totaling over 21 billion pesos. These are not long-term promises or declarations of intent. They are plants under construction, production lines in expansion, and technologies that Mexico did not manufacture before.
The announcement was part of the Mexico Plan and includes seven drug production projects in the country, also linked to clinical research. The Secretary of Health, David Kershenobich, was direct in framing what is at stake: beyond the figure, what is being built is the possibility of industrial development and access to drug production within the national territory.
Individual projects tell the story with more precision. Laboratorios Kener leads with 5.36 billion pesos for the production of biotechnological products in Toluca. Liomont will allocate 4 billion, including an mRNA plant in Mexico City, which would place Mexico among the few countries in the region with the capacity to manufacture this technology. Abbott will invest 3.5 billion in a 20,000 square meter facility in Querétaro to address cardiovascular diseases, chosen for the availability of specialized talent and proximity to universities. Bayer reported progress on its 3 billion peso investment plan to modernize eight production plants and six research centers in the country. Bristol Myers Squibb committed one billion pesos for the next four years, focused on clinical research in oncology, hematology, immunology, and cardiovascular diseases.
The Sheinbaum government also incorporated Birmex as a state lever to drive down drug prices, with an unambiguous message: "We want prices to come down." The mechanism is clear: if the state-owned company sells cheaper, the pressure on private companies increases. The investment is not proposed as a subsidy to the industry, but as a strategic intervention on the price structure that today makes certain drugs inaccessible to millions of Mexicans.
The stated objective of the Mexico Plan is twofold: to reduce dependence on imports of strategic inputs and to open new export routes. Sheinbaum emphasized that the plan seeks to increase national production of strategic goods to reduce external dependence and strengthen exports.
For the next+ analyst collective, this set of investments is a signal of repositioning in global value chains. Mexico has conditions difficult to replicate in other markets in the region: technical talent, consolidated manufacturing infrastructure, and preferential access via USMCA, and the pharmaceutical industry is clearly recognizing this. The bet on building local capacity in biotechnology and mRNA is not just health sovereignty; it is strategic infrastructure that creates highly specialized jobs, attracts clinical research, and positions the country as an exporter in a category of very high added value. For organizations operating in health, manufacturing, or supply chain, the map of opportunities in Mexico has just changed.